



**Silva Pharmaceuticals Limited**

সিলভা ফার্মাসিউটিক্যালস্ লিমিটেড

House # 65, Road # 8/A, Dhanmondi, Dhaka

## Notice of the 24<sup>th</sup> Annual General Meeting

**Notice** is hereby given to all shareholders of Silva Pharmaceuticals Limited (SPL) that the **24<sup>th</sup> Annual General Meeting (AGM)** of the company will be held on Tuesday, 30<sup>th</sup> December 2025, at 11:30 A.M. (Bangladesh Standard Time) through a Hybrid System-combination both virtual participation (via the digital platform: <https://silvaphlagm2025.hybridagmbd.net>) and physical attendance at **Suchona Community Center**, Ring Road, near Krishi Market, Dhaka-1207 - to transact the following businesses:

### AGENDA

1. To receive, consider and adopt the Audited Financial Statements of the company for the year ended 30 June, 2025, together with the Auditors' Report and the Directors' Report thereon;
2. To approve the proposed dividend for the financial year ended 30 June, 2025 as recommended by the Board of Directors;
3. To elect/re-elect Directors in accordance with the relevant provisions of Articles of Association of the company;
4. To grant post-facto approval for the appointment of the Chief Executive Officer (Current Charge);
5. To appoint Statutory Auditors for the financial year 2025-2026 and to fix their remuneration;
6. To appoint Compliance Auditors for the financial year 2025-2026 and to fix their remuneration;

By Order of the Board,

**(Md. Iqbal Hossain)**

Company Secretary

Dated: 27 November, 2025

### Notes:

- i. The Shareholders, whose names will appear in the Share Register of the Company or Depository Register (CDBL) on the **"Record Date"** i.e. **Monday, 01 December, 2025** respectively are eligible to attend/participate and vote in the Annual General Meeting (AGM) through Hybrid System and entitled to the dividend.
- ii. A Members entitled to attend and vote in the Annual General Meeting, may appoint a proxy to attend and vote on his/her stead. The proxy Form must be affixed with requisite revenue stamp of Tk. 100.00 and be sent through email to Silva Pharmaceuticals Limited's Registered Office at [share@silvapharma.com](mailto:share@silvapharma.com) at least 48 hours before the schedule time of the meeting.
- iii. Pursuant to the BSEC Notification No. BSEC/CMRRCD/2006-158/208/Admin/81 dated June 20, 2018 soft copy of the Annual Report 2024-2025 will be sent to the Shareholder's respective e-mail addresses as available with us. The Annual Report 2024-2025 will also be available in the company's website at [www.silvapharma.com](http://www.silvapharma.com). AGM joining procedure will be notified later through e-mail/SMS/website of the company in due course.
- iv. The Members will be able to submit their questions/comments through virtual link/e-mail [share@silvapharma.com](mailto:share@silvapharma.com) 24 hours before commencement of the AGM and during the AGM. For logging into the system, the members need to put their 16-digit Beneficiary Owner (BO) ID/Folio number and other credentials as proof of their identity by visiting the link <https://silvaphlagm2025.hybridagmbd.net>.
- v. Shareholders are requested to login to the system prior to starting of the meeting at 11:30 A.M. on Tuesday, 30 December 2025. The webcast will start at 11:20 A.M. Please contact at 01790948155 for any queries in accessing the virtual meeting.
- vi. The Members are requested to update their respective BO Accounts with 12 Digit e-TIN, Bank Account, Mailing Address and Contact Number through their respective Depository Participant (DP).
- vii. The corporate shareholders need to send their authorization letter to join the meeting of the company at least 48 hours before the commencement of the AGM.

**N.B.:** In compliance with the Bangladesh Securities and Exchange Commission's circular no. SEC/CMRRCD/2009-193/154 dated October 24, 2013 and The Listing Regulations 2015 of Stock Exchanges, no gift/gift coupon/food box/benefit in cash or in kind shall be distributed / paid to the shareholders for attending the ensuing 24<sup>th</sup> Annual General Meeting.